Pricing Availability   Qty

Save up to 40% on RUO Reagents with BIOSPRING24 (see details)

Description: 5-HT2A antagonist; also D2 antagonist; atypical antipsychotic
Chemical Name: 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Purity: ≥99% (HPLC)
Citations (4)
Literature (3)

Biological Activity for Olanzapine

Olanzapine is an antagonist of 5-HT2A and dopamine D2 receptors (Ki values are 4 and 11 nM respectively). Also displays affinity for a range of other receptors including D1 and D4, 5-HT2C, α1, H1 and M1-4 receptors (Ki values range between 1.9 and 31 nM). Atypical antipsychotic. Displays anticholinergic properties. Also a highly potent activator of hM4Di DREADDs (EC50 values are 5 nM in vitro and 7 nM in vivo).

Compound Libraries for Olanzapine

Olanzapine is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.

Technical Data for Olanzapine

M. Wt 312.43
Formula C17H20N4S
Storage Store at +4°C
Purity ≥99% (HPLC)
CAS Number 132539-06-1
PubChem ID 4585
Smiles CC4=CC2=C(S4)NC1=CC=CC=C1N=C2N3CCN(C)CC3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Olanzapine

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 31.24 100
1eq. HCl 31.24 100

Preparing Stock Solutions for Olanzapine

The following data is based on the product molecular weight 312.43. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.2 mL 16 mL 32.01 mL
5 mM 0.64 mL 3.2 mL 6.4 mL
10 mM 0.32 mL 1.6 mL 3.2 mL
50 mM 0.06 mL 0.32 mL 0.64 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for Olanzapine

Certificate of Analysis / Product Datasheet
Select another batch:

References for Olanzapine

References are publications that support the biological activity of the product.

Tollefson and Taylor (2000) Olanzapine: preclinical and clinical profiles of a novel antipsychotic agent. CNS Drug Reviews 6 303

Moore et al (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J.Pharmacol.Exp.Ther. 262 545 PMID: 1354253

Bymaster et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanz. Neuropsychopharmacology 14 87 PMID: 8822531

If you know of a relevant reference for Olanzapine, please let us know.

View Related Products by Product Action

View all 5-HT2A Receptor Antagonists

Keywords: Olanzapine, Olanzapine supplier, 5ht2a, 5ht2c, serotonergics, dopamine, dopaminergics, d2, antagonists, atypical, antipsychotics, thienobenzodiazepine, chemogenetics, DREADD, D2, Receptors, DREADDs, 5-HT2A, 4349, Tocris Bioscience

4 Citations for Olanzapine

Citations are publications that use Tocris products. Selected citations for Olanzapine include:

Mitradas M et al (2020) Serotonin 2A (5-HT2A) receptor affects cell-matrix adhesion and the formation and maintenance of stress fibers in HEK293 cells. Sci Rep 10 21675 PMID: 33303826

Pérez-Gómez et al (2018) A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia. Nat Commun 9 5272 PMID: 30532051

Joshi and Panicker (2019) Identifying the In Vivo Cellular Correlates of Antipsychotic Drugs. Eneuro 5 PMID: 30713996

Czysz et al (2015) Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. Nat Methods 40 766 PMID: 25249058

Do you know of a great paper that uses Olanzapine from Tocris? Please let us know.

Reviews for Olanzapine

There are currently no reviews for this product. Be the first to review Olanzapine and earn rewards!

Have you used Olanzapine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

5-HT Receptors Scientific Review

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.